Literature DB >> 12751784

The parasite-specific trypanothione metabolism of trypanosoma and leishmania.

R Luise Krauth-Siegel1, Svea K Meiering, Heide Schmidt.   

Abstract

The bis(glutathionyl)spermidine trypanothione exclusively occurs in parasitic protozoa of the order Kinetoplastida, such as trypanosomes and leishmania, some of which are the causative agents of several tropical diseases. The dithiol is kept reduced by the flavoenzyme trypanothione reductase and the trypanothione system replaces in these parasites the nearly ubiquitous glutathione/glutathione reductase couple. Trypanothione is a reductant of thioredoxin and tryparedoxin, small dithiol proteins, which in turn deliver reducing equivalents for the synthesis of deoxyribonucleotides as well as for the detoxification of hydroperoxides by different peroxidases. Depending on the individual organism and the developmental state, the parasites also contain significant amounts of glutathione, mono-glutathionylspermidine and ovothiol, whereby all four low molecular mass thiols are directly (trypanothione and mono-glutathionylspermidine) or indirectly (glutathione and ovothiol) maintained in the reduced state by trypanothione reductase. Thus the trypanothione system is central for any thiol regeneration and trypanothione reductase has been shown to be an essential enzyme in these parasites. The absence of this pathway from the mammalian host and the sensitivity of trypanosomatids toward oxidative stress render the enzymes of the trypanothione metabolism attractive target molecules for the rational development of new drugs against African sleeping sickness, Chagas' disease and the different forms of leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751784     DOI: 10.1515/BC.2003.062

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  34 in total

1.  Antileishmanial activity of imidothiocarbamates and imidoselenocarbamates.

Authors:  David Moreno; Daniel Plano; Ylenia Baquedano; Antonio Jiménez-Ruiz; Juan Antonio Palop; Carmen Sanmartín
Journal:  Parasitol Res       Date:  2010-10-05       Impact factor: 2.289

2.  In silico work flow for scaffold hopping in Leishmania.

Authors:  Barnali Waugh; Ambarnil Ghosh; Dhananjay Bhattacharyya; Nanda Ghoshal; Rahul Banerjee
Journal:  BMC Res Notes       Date:  2014-11-17

3.  Induction of oxidative stress in Trypanosoma brucei by the antitrypanosomal dihydroquinoline OSU-40.

Authors:  Shanshan He; Alex Dayton; Periannan Kuppusamy; Karl A Werbovetz; Mark E Drew
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

4.  Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity.

Authors:  Georgina A Holloway; William N Charman; Alan H Fairlamb; Reto Brun; Marcel Kaiser; Edmund Kostewicz; Patrizia M Novello; John P Parisot; John Richardson; Ian P Street; Keith G Watson; Jonathan B Baell
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

5.  Novel role of calmodulin in regulating protein transport to mitochondria in a unicellular eukaryote.

Authors:  Abhishek Aich; Chandrima Shaha
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

6.  A thioredoxin family protein of the apicoplast periphery identifies abundant candidate transport vesicles in Toxoplasma gondii.

Authors:  Amy E DeRocher; Isabelle Coppens; Anuradha Karnataki; Luke A Gilbert; Michael E Rome; Jean E Feagin; Peter J Bradley; Marilyn Parsons
Journal:  Eukaryot Cell       Date:  2008-06-27

7.  Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening.

Authors:  Georgina A Holloway; Jonathan B Baell; Alan H Fairlamb; Patrizia M Novello; John P Parisot; John Richardson; Keith G Watson; Ian P Street
Journal:  Bioorg Med Chem Lett       Date:  2006-12-03       Impact factor: 2.823

8.  In silico structural characterization of protein targets for drug development against Trypanosoma cruzi.

Authors:  Carlyle Ribeiro Lima; Nicolas Carels; Ana Carolina Ramos Guimaraes; Pierre Tufféry; Philippe Derreumaux
Journal:  J Mol Model       Date:  2016-09-24       Impact factor: 1.810

Review 9.  Structure-based ligand design and the promise held for antiprotozoan drug discovery.

Authors:  William N Hunter
Journal:  J Biol Chem       Date:  2008-12-22       Impact factor: 5.157

10.  Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis.

Authors:  Leah S Torrie; Susan Wyllie; Daniel Spinks; Sandra L Oza; Stephen Thompson; Justin R Harrison; Ian H Gilbert; Paul G Wyatt; Alan H Fairlamb; Julie A Frearson
Journal:  J Biol Chem       Date:  2009-10-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.